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Introduction: Pembrolizumab is a selective humanized IgG4 kappa monoclonal 
antibody that inhibits the programmed death-1 (PD-1) receptor, an integral 
component of immune checkpoint regulation in the tumor microenvironment. 
Despite the discovery of clinically-actionable driver mutations in genomic subsets of 
patients, lung cancer remains a leading cause of cancer-related death worldwide for 
both females and males.1,2 Platinum-based chemotherapy remains the preferred 
first-line treatment for most patients with advanced or metastatic non-small cell lung 
cancer (NSCLC) without targetable genomic alterations. 
Materials and methods: Our statistical population included 94 male patients with 
esophageal cancer and 83 samples as control group. DNA was extracted using 
ethanol-chloroform precipitation method. The designed complementary sequence 
was amplified by PCR method, and specific fragments were excised using RFLP 
method. Finally, data were analyzed with SPSS Ver. 22 software 
Results:Based on the results, there were no significant correlations between 
heterozygote genotypes and esophageal cancer in the patients group (OR = 1.17 
95%Cl = 0.61-1.49). However, significant correlations were found between 
dominant homozygotes and the incidence of disease (P = 0.01 95%Cl = 0.31 – 0.92 
OR = 0.019). 
Conclusion: The results show that mutations in the Pembrolizumab for the treatment 
of PD-L1 positive advanced in cell lung cancercan only be used as a biomarker for 
detecting male esophageal cancer in dominant homozygous people with familial 
marriages. 
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